IQVIA Holdings: Strong H2 Outlook With Buoyant TAS, RWE, and RDS Segments Driving Buy Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Stifel Adjusts IQVIA Holdings' Price Target to $312 From $288
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Gilead Sciences Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Argenx Price Target Maintained With a $519.00/Share by Wedbush
Argenx Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $480 From $440
Wedbush Sticks to Its Buy Rating for Argenx Se (ARGX)
Truist Financial Reaffirms Their Buy Rating on Argenx Se (ARGX)
Truist Securities Adjusts Price Target on Argenx to $540 From $480, Maintains Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), Biogen (BIIB) and Sartorius (GB:0NIR)
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Jefferies Adjusts Price Target on Amgen to $380 From $375